July 31, 2012 -- Nanosonics (ASX: NAN) today announced the appointment of Mr Michael Kavanagh to the position of non-Executive Director on the Nanosonics Board. Mr Kavanagh is a highly experienced executive with international experience, having worked for more than 20 years in the area of healthcare marketing. He is currently Senior Vice President of Global Marketing for the major Australian medical device company Cochlear, a position he’s held for more than nine years.
“We are delighted to welcome Michael to the Nanosonics’ Board. His experience and depth of knowledge in global medical device market place is an invaluable addition to our Board. This comes at a time that the Company is entering many markets and is evaluating several opportunities for its platform technologies.” said Nanosonics Chairman Maurie Stang.
“Nanosonics is a great example of Australian Innovation. The global opportunities the company has identified based on its unique offering in disinfection and sterilisation are very attractive. I look forward to working with the Board of Directors and the Senior Executive Team to drive Nanosonics’ growth in the years to come” said Mr Kavanagh.
For further information, please contact:
Dr Ron Weinberger, Managing Director, +61 2 8063 1600
McGregor Grant, Chief Financial Officer, +61 8063 1600
Tom Donovan, Media Enquiries, + 61 3 8866 4722
Nanosonics develops easy to use, environmentally friendly and quality assured products for the infection control market.
Nanosonics is committed to preventing healthcare-associated infections (HAIs), through its first product, Trophon® EPR which is commercially available in the United States, Australia and New Zealand.
Trophon® EPR is the next generation in ultrasound probe disinfection. Nanosonics identified an unmet need in the market for fast, safe, eco-friendly probe disinfection. This unique platform technology effectively disinfects the probe including the shaft and handle - in just seven minutes between patients.
HAIs are infections caused by a wide variety of common and unusual bacteria, fungi, and viruses during the course of receiving medical care. HAI’s are the fourth largest cause of fatality in the United States each year. The Center for Disease Control and Prevention (CDC) estimates that as many as two million people suffer from HAIs annually in the U.S, resulting in more than 100,000 deaths.
Disinfection and sterilization of medical equipment are essential for ensuring there is no transmission of infectious pathogens between patients thereby reducing HAI's. Not all medical instruments can be sterilized due to heat sensitivity and therefore the FDA & CDC recommend high level disinfection (HLD) of these devices. Intracavity ultrasound probes are one such medical device that requires high level disinfection.
Nanosonics Ltd was founded in 2001 and headquartered in Sydney Australia with offices in the USA (Nanosonics Inc) and Europe (Nanosonics Europe GmbH).
You can read more about Nanosonics and its products at www.nanosonics.com.au